Archives
-
Human iPSC Sensory Neurons Model HSV-1 Latency
2026-08-22
Oh et al. developed a scalable human induced pluripotent stem cell-derived sensory neuron system that supports experimentally defined HSV-1 latency and reactivation. The model combines neuronal functional validation with virological, transcriptional, and chromatin-based criteria, providing a human-relevant platform for studying neuron-intrinsic latency mechanisms.
-
Sulfo-NHS-SS-Biotin: Practical Labeling Guide
2026-08-22
Sulfo-NHS-SS-Biotin provides water-compatible, amine-reactive biotinylation for proteins and intact-cell surface proteins, supporting avidin/streptavidin capture and reversible tag removal. It should be prepared immediately before use and is not appropriate for labeling intracellular targets in intact cells or for workflows that require a permanently retained biotin tag under reducing conditions.
-
3-Methyladenine: Strategy for Translational Autophagy
2026-08-21
3-Methyladenine is more than a conventional autophagy inhibitor: its time-dependent effects on class III and class I PI3K create both mechanistic value and experimental risk. This article connects 3-MA strategy with findings on LARP7, STING degradation, autophagy impairment, and diabetic cardiomyopathy, while providing practical guidance for flux-resolved experiments, cancer research, and translational study design.
-
Obeticholic Acid Workflows for Liver Fibrosis
2026-08-20
Obeticholic Acid enables an FXR-centered workflow for connecting bile acid homeostasis with cholestasis, hepatic inflammation, and fibrosis phenotypes. This practical guide covers hepatocyte assays, chronic injury models, assay controls, solvent handling, and how to interpret FXR results alongside newer Notch–NK fibrosis findings.
-
CCCP: Practical Mitochondrial Assay Design
2026-08-20
Learn how CCCP (carbonyl cyanide m-chlorophenyl hydrazine), SKU B5003, can be used to separate mitochondrial energy failure from nonspecific cytotoxicity in cell-based assays. This scenario-driven guide covers mechanism, controls, solution preparation, morphology interpretation, and vendor-selection criteria.
-
Ionomycin free acid for FAK–FAISL Research
2026-08-19
Use Ionomycin free acid as a controlled calcium perturbation tool to connect intracellular calcium increase with adhesion, FAK stability, and TNBC cell behavior. This workflow complements the FAISL–FAK study while keeping calcium-dependent hypotheses distinct from findings directly demonstrated in the paper.
-
UK-5099 in Whole-Blood Immunometabolism
2026-08-19
UK-5099 (PF-1005023) enables mechanistic analysis of how mitochondrial pyruvate entry shapes immune-cell metabolism. This article presents a decision-focused framework for interpreting whole-blood cytokine assays, separating MPC-specific effects from donor, viability, and substrate-related confounders.
-
LY2603618: Chk1 Inhibitor Research Guide
2026-08-18
LY2603618 is a selective Chk1 inhibitor that disrupts checkpoint control, DNA damage signaling, and mitotic progression in cancer research models. Product information supports its use in non-small cell lung cancer and colon cancer studies, including gemcitabine-combination experiments, while emphasizing research-use-only boundaries.
-
Nonselective β-Blockers and HCT Engraftment
2026-08-18
This study shows that carvedilol, a nonselective β-adrenergic receptor antagonist, can impair hematopoietic regeneration after allogeneic hematopoietic cell transplantation (HCT), whereas β1-selective metoprolol does not produce the same pattern. Mouse experiments and human transplant cohorts connect broad β-adrenergic blockade with delayed platelet engraftment and lower survival, particularly when posttransplant chemotherapy is used for graft-versus-host disease prophylaxis.
-
WRN–MMR Synthetic Lethality in MSI Colorectal Cancer
2026-08-17
The reference study identifies a causal p53/PUMA apoptotic mechanism behind the selective dependence of mismatch repair-deficient, microsatellite-unstable colorectal cancer cells on WRN helicase. Its genetic, isogenic, pharmacologic, and xenograft experiments support p53 status as a practical determinant of response to WRN-directed strategies, while also highlighting the need to distinguish WRN biology from broader RecQ-helicase inhibition.
-
STNvac Builds TLS Immunity in Liver Cancer
2026-08-17
Lin et al. developed a spleen-targeted neoantigen mRNA vaccine, STNvac, that produced strong antitumor activity in orthotopic hepatocellular carcinoma models. The study links efficacy to ISG15-positive CD8-positive T cells, GZMA-F2R-mediated interactions with antigen-presenting cells, and tertiary lymphoid structure formation, providing a mechanistic framework for organ-targeted cancer vaccination.
-
miR-24-3p/Sp1/PI3K Axis in Doxorubicin Heart Failure
2026-08-16
The reference study identifies miR-24-3p as a pathogenic regulator of doxorubicin-induced heart failure, acting through suppression of the Sp1/PI3K signaling axis. By combining rat and H9c2 cardiomyocyte models with genetic manipulation, pathway inhibitors, and dual-luciferase validation, the work provides a mechanistic framework for studying apoptosis and oxidative stress in myocardial injury.
-
FAST Nutraceutical Nanoparticles: Study Analysis
2026-08-15
The reference study presents Facilitated Self-Assembling Technology (FAST) as a food-grade, surfactant-free route for producing stable nanoparticles from poorly soluble nutraceuticals. Its findings indicate that hybrid formulations can improve colloidal behavior and simulated gastric stability while retaining cellular compatibility, although further quantitative bioavailability and scale-up studies are needed.
-
Sodium Ascorbate in Cancer Research Workflows
2026-08-14
Sodium Ascorbate gives oncology laboratories a practical way to probe ROS-linked cancer cell injury in glioblastoma and prostate models. This guide connects stock preparation, time-resolved assays, and troubleshooting with a separate biomarker framework for interpreting tumor–immune interactions in ESCC research.
-
131I-MIBG + PARP Inhibition in PPGL Models
2026-08-14
This study tests a synthetic-lethality strategy for norepinephrine transporter-overexpressing pheochromocytoma and paraganglioma models by combining 131I-MIBG with the PARP inhibitor fluzoparib. The combination produced stronger cell-cycle arrest and apoptosis than either treatment alone, while SDHB suppression preferentially increased sensitivity to fluzoparib rather than to 131I-MIBG.